Economia

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Experiences Heavier than Usual Trading Volume

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Experiences Heavier than Usual Trading Volume

The firm owned 2,445,007 shares of the medical equipment provider's stock after selling 346,403 shares during the period. North Star Asset Management Inc.'s holdings in Zimmer Biomet Holdings were worth $5,519,000 as of its most recent filing with the SEC. State Street Corp raised its position in Zimmer Biomet Holdings by 2.4% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider's stock worth $602,159,000 after buying an additional 987,398 shares during the last quarter. Point72 Asset Management L.P. increased its position in Zimmer Biomet Holdings by 230.3% in the first quarter. The value of the company's investment in Zimmer Biomet Holdings, Inc. decreased from $72,000 to $66,000 decreasing 8.3% for the reporting period. Sandy Spring Bank boosted its position in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider's stock worth $737,000 after buying an additional 450 shares during the period. Nordea Investment Management AB raised its position in Zimmer Biomet Holdings by 25.0% in the first quarter.

The actual size of Jana's stake in the company is not yet clear, nor are the hedge fund's plans. Zimmer Biomet Holdings has $158 highest and $92 lowest target. (NYSE:ZBH). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.10. If the $143.99 price target is reached, the company will be worth $2.46 billion more. The firm has a 50 day moving average of $123.43 and a 200-day moving average of $117.75. The company had revenue of $1.98 billion for the quarter, compared to the consensus estimate of $1.96 billion.

06/07/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Citigroup. During the same quarter in the previous year, the firm earned $2.00 EPS. They expect $2.08 earnings per share, down 5.45% or $0.12 from last year's $2.2 per share.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date has been established as Wednesday the 21st of June 2017. If you are viewing this story on another site, it was stolen and republished in violation of worldwide copyright and trademark law. The legal version of this story can be accessed at https://sportsperspectives.com/2017/07/16/oppenheimerfunds-inc-lowers-position-in-zimmer-biomet-holdings-inc-zbh-updated-updated.html.

Jana Partners was granted regulatory clearance on Thursday for its purchase of shares in medical device maker Zimmer Biomet Holdings Inc, in a sign that the hedge fund is set to build its stake and press for changes at the company.

06/29/2017 - Cantor Fitzgerald began new coverage on Zimmer Biomet Holdings, Inc. giving the company a " rating. GLG LLC now owns 10,058 shares of the medical equipment provider's stock worth $1,038,000 after buying an additional 639 shares during the period. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday. Stifel Nicolaus reissued a "hold" rating and set a $125.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday. UBS downgraded the shares of ZBH in report on Thursday, December 15 to "Sell" rating. The stock presently has an average rating of "Buy" and an average target price of $137.19.

In related news, insider David C. Dvorak sold 87,331 shares of the company's stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. Following the completion of the sale, the insider now directly owns 381,886 shares of the company's stock, valued at approximately $44,478,262.42. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. VP/Gen Counsel/Secretary sold $725,276 worth of shares at an average price of $116.98 on May 5th. Insiders have sold a total of 111,262 shares of company stock worth $13,103,927 over the last 90 days. The firm's institutional ownership remained 86.80% while insider ownership included 0.20%.

Zimmer Biomet Holdings, Inc.is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.